Meanwhile, ALKBH5 inhibitors can significantly improve immunotherapy efficacy, providing new possibilities for targeted therapy of colorectal cancer, melanoma, and other malignant tumors. This evidence concerns the gene ALKBH5 and colorectal cancer.